EP Patent

EP4233861A3 — Compositions for treatment of essential tremor

Assigned to Ovid Therapeutics Inc · Expires 2023-10-11 · 3y expired

What this patent protects

The invention relates to a compound for use in a method of treating status epilepticus, the compound being ganaxolone and the method comprising administering to a human patient diagnosed with status epilepticus an effective amount of ganaxolone, wherein the effective amount of ga…

USPTO Abstract

The invention relates to a compound for use in a method of treating status epilepticus, the compound being ganaxolone and the method comprising administering to a human patient diagnosed with status epilepticus an effective amount of ganaxolone, wherein the effective amount of ganaxolone is administered as an intravenous infusion to provide a ganaxolone plasma concentration of less than 900 ng hr/ml.

Drugs covered by this patent

Patent Metadata

Patent number
EP4233861A3
Jurisdiction
EP
Classification
—
Expires
2023-10-11
Drug substance claim
No
Drug product claim
No
Assignee
Ovid Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.